A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unr
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
September 6, 2018
End Date
August 31, 2023
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
September 6, 2018
End Date
August 31, 2023